AstraZeneca Pulls Twitter Ads, Showing Risks Of Expansive Social Media Platforms
This article was originally published in The Pink Sheet Daily
Executive Summary
Company thought sponsored messages on AP’s feed were unbranded, but realized drug name showed up in expanded tweet. Did intricacies of the platform produce an inadvertent violation?
You may also be interested in...
Social Media Marketing: FDA’s Old-Time Approach May Turn Industry Away
Draft guidances say tweets about a product must balance benefit and risk information, and firms cannot be selective in correcting information on third-party sites.
Social Media For Pharma: Focus On Building Community, Not Brands
Using social media as a marketing tool should be about building a community and not necessarily focused on brand marketing, Zoetis’ digital strategy manager tells conference attendees.
Keywords Not Major Advertising Enforcement Concern, FDA Says
FDA says keywords don’t need OPDP’s formal review, but that doesn’t mean they don’t have an opinion about how they’re used.